BBAL — New York Health Care Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$5.20m
- $44.40m
Annual income statement for New York Health Care, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2003 December 31st | R2004 December 31st | 2005 December 31st | 2006 December 31st | 2007 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 38.6 | 42.3 | 44.7 | 45.6 | 44.4 |
Cost of Revenue | |||||
Gross Profit | 6.71 | 7.5 | 7.64 | 8.81 | 7.77 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 60.7 | 48.5 | 53.8 | 49.3 | 45.6 |
Operating Profit | -22.1 | -6.23 | -9.09 | -3.79 | -1.22 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -22.1 | -6.19 | -9.03 | -3.68 | -0.978 |
Provision for Income Taxes | |||||
Net Income After Taxes | -22.1 | -6.12 | -9.1 | -3.76 | -1.05 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -22.1 | -6.07 | -6.32 | -3.76 | -1.05 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -22.1 | -6.07 | -6.32 | -3.76 | -1.05 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.433 | -0.2 | -0.285 | -0.095 | -0.016 |
Dividends per Share |